NEW YORK (GenomeWeb News) – Biocius Life Sciences said today that it is now an independent operating company after completing its spin out from parent company Biotrove, which was recently acquired by Life Technologies.

Biocius said that it now holds all of the intellectual property related to the RapidFire mass spectrometry platform formerly owned by Biotrove; and that it will employ all former employees of Biotrove's RapidFire business unit.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.

Oct
10
Sponsored by
PerkinElmer

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.